Pharmacokinetics and pharmacodynamics of ε-aminocaproic acid in horses

American Journal of Veterinary Research

Volumn 68, Issue 9, 2007, Pages 1016-1021

  Ross, Julie ^a,b   Dallap, Barbara L ^a   Dolente, Brett A ^a   Sweeney, Raymond W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ANIMAL HEALTH TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIPLASMIN; FIBRINOGEN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; FIBRINOLYSIS; HORSE; MEAN RESIDENCE TIME; NONHUMAN; PHARMACODYNAMICS; THROMBOCYTE FUNCTION; TIME; VISCOELASTICITY; ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; BLOOD; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NONPARAMETRIC TEST; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

ANIMALIA; EQUIDAE;

6-AMINOCAPROIC ACID; ANIMALS; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; AREA UNDER CURVE; FEMALE; FIBRINOGEN; HALF-LIFE; HORSES; INFUSIONS, INTRAVENOUS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; STATISTICS, NONPARAMETRIC;

EID: 34548601342     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.9.1016     Document Type: Article

References (28)

1. Ririe DG, James RL, O'Brien JJ, et al. The pharmacokinetics of E-aminocaproic acid in children undergoing surgical repair of congenital heart defects. Anesth Analg 2002;94:44-49.
2. Frederiksen MC, Bowsher DJ, Ruo TI, et al. Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects. Clin Pharmacol Ther 1984;35:387-393.
3. Daily PO, Lamphere JA, Dembitsky WP. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. J Thor Cardiovasc Surg 1994;108:1:99-104.
4. Eberle B, Mayer E, Hafner G, et al. High dose E-aminocaproic acid versus aprotonin: antifibrinolytic efficacy in first-time coronary operations. Ann Thorac Surg 1998;65:667-673.
5. Fish SS, Pancorbo S, Berkseth R. Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis. J Neurosurg 1981;54:736-739.
6. Mannucci PM. Drug therapy: hemostatic drugs. N Engl J Med 1998;339:245-253.
7. Downard CD, Betit P, Chang RW, et al. impact of Amicar in hemorrhagic complications of ECMO: a ten year review. J Pediatr Surg 2003;38:1212-1216.
8. Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al. The effect of Amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study. Spine 2004;29:233-238.
9. Heidmann P, Tornquist SJ, Qu A, et al. Laboratory measure of hemostasis and fibrinolysis after intravenous administration of E-aminocaproic acid in clinically normal horses and ponies. Am J Vet Res 2005;66:313-318.
10. Kahn MB, Palmer S, Marlar RA. A modified quantitative whole blood clot lysis method for general laboratory analysis of fibrinolysis. Thromb Res 1990;59:171-181.
11. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. influence of E-aminocarboxylic acids. Biochem Biophys Acta 1975;393:55-65.
12. Ray MJ, Hales M, Marsh N. Epsilon-aminocaproic acid promotes the release of α2-antiplasmin during and after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001;12:129-135.
13. Slaughter TF, Faghih F, Greenberg CS, et al. The effects of epsilon-aminocaproic acid in fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997;85:1221-1226.
14. Hett DA, Walker D, Pilkington SN, et al. Sonoclot analysis. Br J Anaesth 1995;75:771-776.
15. Sonoclot coagulation and platelet function analyzer with graphics printer operator's manual, Version 4.0, Arvada, Colo: Sienco, Inc, 2-7.
16. Tuman EJ, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69-75.
17. Dallap BL. Evaluation of hemostatic function in the equine critical care patient: old and new techniques, in Proceedings. 8th Annu Meet Int Vet Emerg Crit Care Soc 2002;625-629.
18. Dallap BL. Coagulopathy in the equine critical care patient. Vet Clin North Am Equine Pract 2004;20:231-251.
19. Quash T, Tippens M, Szlam F, et al. Quantitative assessment of fibrinogen cross-linking by E-aminocaproic acid in patients with end stage liver disease. Liver Transpl 2004;10:123-128.
20. Prasse KW, Allen D, Moore JN, et al. Evaluation of coagulation and fibrinolysis during the prodromal stages of carbohydrate-induced acute laminitis in horses. Am J Vet Res 1990;51:1950-1955.
21. Dallap B, Dolente B, Boston R. Coagulation profiles in 27 horses with large colon volvulus. J Vet Emerg Crit Care 2003;13:215-225.
22. Yamaoka K, Nakagawa T, Uno T Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175
23. Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14:41-47.
24. Butterworth J, Robert L, Lin Y, et al. Pharmacokinetics of E-aminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 1999;90:1624-1635.
25. Eisses MJ, Seidel K, Gabriel AS, et al. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach. Anesth Analg 2004;98:1208-1216.
26. Manjunath G, Fozailoff A, Mitcheson D. Epsilon-aminocaproic acid and renal complications: case report and review of the literature. Clin Nephrol 2002;58:63-67.
27. Cooper RJ Jr, Abrams J, Frazier OH. Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. J Thorac Cardiovasc Surg 2006;131:963-968.
28. Ray M, Hatcher S, Whitehouse SL, et al. Aprotonin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty: a prospective randomized double-blind placebo-controlled study. J Thromb Haemost 2005;3:1421-1427.